



(51) International Patent Classification:

C12N 5/0783 (2010.01) C07K 14/435 (2006.01)
A61P 35/00 (2006.01) C07K 14/705 (2006.01)
A61P 37/00 (2006.01) C12N 5/10 (2006.01)
A61P 7/00 (2006.01) C12Q 1/6809 (2018.01)
C12N 5/0789 (2010.01)

(21) International Application Number:

PCT/US2023/076110

(22) International Filing Date:

05 October 2023 (05.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/413,338 05 October 2022 (05.10.2022) US

(71) Applicant: GARUDA THERAPEUTICS, INC. [US/US];
215 First St., Suites 340-350, Cambridge, MA 02142 (US).

(72) Inventor: SHAH, Dhvanit; c/o Garuda Therapeutics, Inc.,
215 First St., Suites 340-350, Cambridge, MA 02142 (US).


(74) Agent: HAYMAN, Mark, L. et al.; Morgan, Lewis &
Bockius LLP, 1701 Market Street, Philadelphia, PA 19103
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: PLURIPOTENT STEM CELL-DERIVED T CELL POPULATIONS AND PROGENITORS THEREOF

FIG. 25



(57) Abstract: In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for efficient *ex vivo* processes for developing progenitor T cells and T cell populations (including but not limited to CD4+CD8+ "double positive" T cells, as well as single positive CD4+ T helper cells and CD8+ cytotoxic T cells, and T regulatory cells) from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or more closely resemble the corresponding lineage isolated from peripheral blood or lymphoid organs. The present invention in some aspects provides isolated cells and cell compositions produced by the methods disclosed herein, as well as methods for cell therapy.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*